Preoperative use of anti-tumor necrosis factor therapy in Crohn's disease: promises and pitfalls
Intestinal Research
;
: 160-165, 2017.
Artículo
en Inglés
| WPRIM
| ID: wpr-117647
ABSTRACT
Recent advances in medical and surgical therapy were achieved during the last two decades in the management of Crohn's disease (CD). Anti-tumor necrosis factor (anti-TNF) agents are widely used worldwide. However, a significant proportion of patients still need surgical resections. The impact of previous exposure to these agents on the perioperative and postoperative outcomes is still controversial. In this critical review, we aimed to position the strategy of intentional preoperative use of anti-TNF agents in the management of CD. The indications and contraindications for this strategy are detailed, and despite scarce evidence, the possible advantages and disadvantages of the intentional use of anti-TNF agents before abdominal surgery in CD are discussed.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Cuidados Preoperatorios
/
Enfermedad de Crohn
/
Factor de Necrosis Tumoral alfa
/
Necrosis
Límite:
Humanos
Idioma:
Inglés
Revista:
Intestinal Research
Año:
2017
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS